LYMPHOCYTE ACTIVATION GENE - 3 PROTEIN MARKET ANALYSIS

Lymphocyte Activation Gene - 3 Protein Market, by Drug (BMS-986016 (Relatlimab), IMP321, IMP701, MGD013, and Others), by Cancer Type (Breast Cancer, Melanoma, Solid Tumors, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Nov 2024
Code : CMI2027
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Lymphocyte Activation Gene - 3 Protein Market Key Player

Key players operating in the global lymphocyte activation gene - 3 protein market include, Bristol-Myers Squibb, Icell Kealex Therapeutics, Incyte Corporation, MacroGenics, Inc., GlaxoSmithKline Plc, Crescendo Biologics Ltd, Regeneron Pharmaceuticals Inc., Sutro Biopharma Inc., Symphogen A/S, and Immutep Ltd.